Healthspan Capital's Sebastian Brunemeier discusses longevity biotech on Real Vision
April 19, 2021
This week, Healthspan Capital co-founder and General Partner, Sebastian Brunemeier was featured in a 1-hour interview on Real Vision with Brent Johnson. The two discuss aging biology, promising areas of longevity biotechnology, and venture capital.
According to visionary Sebastian Brunemeier, only recently have we been able to understand the “fundamental molecular and cellular biology of the aging process.” Newfound technologies have allowed scientists to extend the healthy lifespan of mice by up to 30%, and he believes this research can, and will, eventually be applied to slow the aging process for humans as well. But how big is the market around longevity biotech? Since welcoming early investors like Peter Thiel and Bob Nelson, Brunemeier says there’s “a huge industry building around longevity biotech” and reveals the potential for economic change. Recorded on February 18, 2022.
About Real Vision
Real Vision is one of the most viewed financial analysis and investment media platforms in the world. Founded in 2014 by ex-Goldman Sachs executive Raoul Pal, the platform features video interviews with top minds in finance and investment including Stanley Druckenmiller, Jefferey Gundlach, Mike Novogratz, Josh Wolfe, and many others. The Real Vision YouTube channel has accumulated 638k subscribers with over 80M total views.
About Healthspan Capital
Healthspan Capital is a venture capital firm with a mission to broadly invest and support longevity biotechnology ("LongBio") companies developing therapeutics to extend healthy human lifespan. We believe that rejuvenation biotechnology is the future of medicine.
Healthspan Capital was founded in 2021 by Sebastian Brunemeier, Nathan Cheng, and Michael Chinen. Our fund was the first publicly accessible longevity venture fund listed on Angel List.